SAINT PREX, Switzerland, 17 August 2015 – Ferring Pharmaceuticals announced initiation of patient enrollment in a phase 2b/3 clinical trial of selepressin for the treatment of septic shock, a life-threatening complication of infection affecting millions of people worldwide annually. The trial, SEPSIS-ACT, will be conducted at 50-60 sites in Europe and the United States and will enroll 1800 patients).
Newsroom
Monday, 17 August 2015